{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:04:00Z","timestamp":1779923040178,"version":"3.53.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.japh.2020.07.002","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T01:34:34Z","timestamp":1597109674000},"page":"943-950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prescription drug monitoring programs in community pharmacy: An exploration of pharmacist time requirements and labor cost"],"prefix":"10.1016","volume":"60","author":[{"given":"Charlie","family":"Upton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Gernant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel M.","family":"Rickles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.japh.2020.07.002_bib2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.amepre.2018.12.009","article-title":"U.S. Emergency Department visits resulting from nonmedical use of pharmaceuticals, 2016","volume":"56","author":"Geller","year":"2019","journal-title":"Am J Prev Med"},{"issue":"7","key":"10.1016\/j.japh.2020.07.002_bib3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2013.272","article-title":"Pharmaceutical overdose deaths, United States, 2010","volume":"309","author":"Jones","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.japh.2020.07.002_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/epirev\/mxaa002","article-title":"Prescription drug monitoring programs and prescription opioid-related outcomes in the United States","author":"Puac-Polanco","year":"2020","journal-title":"Epidemiol Rev"},{"issue":"6","key":"10.1016\/j.japh.2020.07.002_bib8","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/pme.12700","article-title":"How, why, and for whom do emergency medicine providers use prescription drug monitoring programs?","volume":"16","author":"Smith","year":"2015","journal-title":"Pain Med"},{"issue":"3","key":"10.1016\/j.japh.2020.07.002_bib9","doi-asserted-by":"crossref","first-page":"484-492","DOI":"10.1377\/hlthaff.2014.1085","article-title":"Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access","volume":"34","author":"Rutkow","year":"2015","journal-title":"Health Aff"},{"issue":"2","key":"10.1016\/j.japh.2020.07.002_bib10","first-page":"86","article-title":"Ethical, legal, and professional challenges posed by controlled medication seekers to healthcare providers, part 2","volume":"7","author":"Solis","year":"2010","journal-title":"Am J Clin Med"},{"issue":"9","key":"10.1016\/j.japh.2020.07.002_bib11","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/AJP.0000000000000180","article-title":"Leading a horse to water: facilitating registration and use of a Prescription Drug Monitoring Program","volume":"31","author":"Deyo","year":"2015","journal-title":"Clin J Pain"},{"issue":"5","key":"10.1016\/j.japh.2020.07.002_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.2042-7174.2012.00202.x","article-title":"Older patient, physician and pharmacist perspectives about community pharmacists' roles","volume":"20","author":"Tarn","year":"2012","journal-title":"Int J Pharm Pract"},{"issue":"5","key":"10.1016\/j.japh.2020.07.002_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.japh.2018.06.003","article-title":"Pharmacists\u2019 attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping review","volume":"58","author":"Johnston","year":"2018","journal-title":"J\u00a0Am Pharm Assoc JAPhA"},{"issue":"2","key":"10.1016\/j.japh.2020.07.002_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.sapharm.2013.05.007","article-title":"The association of subjective workload dimensions on quality of care and pharmacist quality of work life","volume":"10","author":"Chui","year":"2014","journal-title":"Res Soc Admin Pharm RSAP"},{"issue":"4","key":"10.1016\/j.japh.2020.07.002_bib18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.sapharm.2015.09.011","article-title":"Using link analysis to explore the impact of the physical environment on pharmacist tasks","volume":"12","author":"Lester","year":"2016","journal-title":"Res Soc Admin Pharm RSAP"},{"key":"10.1016\/j.japh.2020.07.002_bib19","author":"Data"},{"key":"10.1016\/j.japh.2020.07.002_bib23","unstructured":"Hill T. RE: Leveraging Medicaid Technology to Address the Opioid Crisis. 7500 Security Boulevard: DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services, Mail Stop S2-26-12 Baltimore; 2018:MD 21244\u201321850. Available at: https:\/\/www.medicaid.gov\/federal-policy-guidance\/downloads\/smd18006.pdf. Accessed September 7, 2019."},{"issue":"2","key":"10.1016\/j.japh.2020.07.002_bib24","first-page":"440","article-title":"Big data and the opioid crisis: balancing patient privacy with public health","volume":"46","author":"Butler","year":"2018","journal-title":"J\u00a0Law Med Eth J Am Soc Law Med Eth"},{"issue":"2","key":"10.1016\/j.japh.2020.07.002_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/10826084.2018.1491052","article-title":"Perceived unintended consequences of prescription drug monitoring programs","volume":"54","author":"Yuanhong Lai","year":"2019","journal-title":"Subst Use Misuse"},{"issue":"6","key":"10.1016\/j.japh.2020.07.002_bib28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.sapharm.2018.09.007","article-title":"Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: results from a multi-site qualitative study","volume":"15","author":"Freeman","year":"2019","journal-title":"Res Soc Admin Pharm RSAP"},{"issue":"8","key":"10.1016\/j.japh.2020.07.002_bib29","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.sapharm.2019.01.002","article-title":"Pharmacist utilization of prescription opioid misuse interventions: acceptability among pharmacists and patients","volume":"15","author":"Riley","year":"2019","journal-title":"Res Soc Admin Pharm RSAP"},{"issue":"8","key":"10.1016\/j.japh.2020.07.002_bib30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.sapharm.2018.02.004","article-title":"An opioid dispensing and misuse prevention algorithm for community pharmacy practice","volume":"15","author":"Rickles","year":"2019","journal-title":"Res Soc Adm Pharm"},{"issue":"6","key":"10.1016\/j.japh.2020.07.002_bib32","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1377\/hlthaff.2017.1321","article-title":"Four states with robust prescription drug monitoring programs reduced opioid dosages","volume":"37","author":"Haffajee","year":"2018","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.japh.2020.07.002_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2019.02.010","article-title":"Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing","volume":"199","author":"Strickler","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"10, October","key":"10.1016\/j.japh.2020.07.002_bib38","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1093\/pm\/pny053","article-title":"Physician time burden associated with querying prescription drug monitoring programs","volume":"19","author":"Bachhuber","year":"2018","journal-title":"Pain Med"},{"issue":"20","key":"10.1016\/j.japh.2020.07.002_bib39","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1001\/jama.2011.1712","article-title":"Can prescription drug monitoring programs help limit opioid abuse?","volume":"306","author":"Gugelmann","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.japh.2020.07.002_bib40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugalcdep.2017.12.002","article-title":"Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings","volume":"184","author":"Pauly","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"10.1016\/j.japh.2020.07.002_bib41","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7326\/M17-3074","article-title":"Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: A systematic review","volume":"168","author":"Fink","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.japh.2020.07.002_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drugalcdep.2015.02.010","article-title":"Abrupt decline in oxycodone-caused mortality after implementation of Florida\u2019s Prescription Drug Monitoring Program","volume":"150","author":"Delcher","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.japh.2020.07.002_bib43","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.amepre.2019.07.026","article-title":"Predicting opioid overdose deaths using Prescription Drug Monitoring Program data","volume":"57","author":"Ferris","year":"2019","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.japh.2020.07.002_bib44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/pam.22098","article-title":"Mandatory access prescription drug monitoring programs and prescription drug abuse","volume":"38","author":"Grecu","year":"2019","journal-title":"J\u00a0Policy Anal Manag"},{"issue":"9","key":"10.1016\/j.japh.2020.07.002_bib46","first-page":"1","article-title":"Controlled substance prescribing patterns--prescription behavior surveillance system, Eight states","volume":"64","author":"Paulozzi","year":"2013","journal-title":"Morb Mortal Wkly Rep Surveill Summ"},{"key":"10.1016\/j.japh.2020.07.002_bib50","unstructured":"NCPDP recommendations for improving prescription drug monitoring programs. National Council for Prescription Drug Programs, Inc. Available at: https:\/\/www.ncpdp.org\/NCPDP\/media\/pdf\/wp\/NCPDPPDMPWhitePaper201505.pdf Accessed October 4, 2019;\u00a02015."},{"key":"10.1016\/j.japh.2020.07.002_bib52","author":"Frail"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319120303228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319120303228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:51:30Z","timestamp":1761544290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319120303228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1544319120303228"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2020.07.002","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescription drug monitoring programs in community pharmacy: An exploration of pharmacist time requirements and labor cost","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2020.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}